LC-MS/MS Assay Directly Detects Urinary Bacteria
By LabMedica International staff writers Posted on 30 Oct 2019 |

Image: The Q Exactive HF-X hybrid quadrupole mass spectrometer (Photo courtesy of Thermo Fisher Scientific).
Fast identification of microbial species in clinical samples is essential to provide an appropriate anti-biotherapy to the patient and reduce the prescription of broad-spectrum antimicrobials leading to anti-bioresistances.
Matrix-assisted laser desorption/ionization – time of flight-mass spectrometry (MALDI-TOF-MS) technology has become a tool of choice for microbial identification, but has several drawbacks as it requires a long step of bacterial culture prior to analysis (24 hours), has a low specificity and is not quantitative.
Scientists at the Centre Hospitalier Universitaire de Québec (Québec, QC, Canada) and their colleagues developed a new strategy for identifying bacterial species in urine using specific liquid chromatography–mass spectrometry (LC-MS/MS) peptidic signatures. The team combined several mass spectrometry techniques to develop their assay, starting with shotgun mass spectrometry assays of pure bacterial colonies to develop mass spectral libraries for use in subsequent data-independent acquisition (DIA) assays. They used those DIA assays to detect bacterial peptides in urine samples, quantifying 31,000 peptides from 190 samples containing 15 bacterial species that cause 84% of all urinary tract infections (UTIs).
The sceintists tested these targeted assays in urine samples inoculated with the four most commonly found causes of UTIs (Escherichia coli, Streptococcus agalactiae, Enterococcus faecalis, and Klebsiella pneumonia) at five different concentrations running the experiments with 90-minute LC gradients on a Thermo Fisher Scientific Orbitrap Fusion. They also ran the samples on a Thermo Fisher Q Exactive HF-X using a 30-minute LC gradient. The assays showed 100% accuracy in all inoculations at concentrations above the standard clinical threshold and 97% accuracy overall.
The scientists also compared their direct detection approach to a standard MALDI-TOF workflow, finding that in a set of 27 patients, the two methods agreed on 19 of the samples (seven of which were not infected and nine of which were infected with E. coli), while disagreeing on eight samples, seven of which the MALDI-TOF method identified as infected while the LC-MS/MS approach identified as not infected, though these seven were identified by the MALDI-TOF at the genus, but not species level.
The authors concluded that their work demonstrates the efficiency of the method for the rapid and specific identification of the bacterial species causing UTI and could be extended in the future to other biological specimens and to bacteria having specific virulence or resistance factors. The study was published on October 4, 2019, in the journal Molecular & Cellular Proteomics.
Related Links:
Centre Hospitalier Universitaire de Québec
Matrix-assisted laser desorption/ionization – time of flight-mass spectrometry (MALDI-TOF-MS) technology has become a tool of choice for microbial identification, but has several drawbacks as it requires a long step of bacterial culture prior to analysis (24 hours), has a low specificity and is not quantitative.
Scientists at the Centre Hospitalier Universitaire de Québec (Québec, QC, Canada) and their colleagues developed a new strategy for identifying bacterial species in urine using specific liquid chromatography–mass spectrometry (LC-MS/MS) peptidic signatures. The team combined several mass spectrometry techniques to develop their assay, starting with shotgun mass spectrometry assays of pure bacterial colonies to develop mass spectral libraries for use in subsequent data-independent acquisition (DIA) assays. They used those DIA assays to detect bacterial peptides in urine samples, quantifying 31,000 peptides from 190 samples containing 15 bacterial species that cause 84% of all urinary tract infections (UTIs).
The sceintists tested these targeted assays in urine samples inoculated with the four most commonly found causes of UTIs (Escherichia coli, Streptococcus agalactiae, Enterococcus faecalis, and Klebsiella pneumonia) at five different concentrations running the experiments with 90-minute LC gradients on a Thermo Fisher Scientific Orbitrap Fusion. They also ran the samples on a Thermo Fisher Q Exactive HF-X using a 30-minute LC gradient. The assays showed 100% accuracy in all inoculations at concentrations above the standard clinical threshold and 97% accuracy overall.
The scientists also compared their direct detection approach to a standard MALDI-TOF workflow, finding that in a set of 27 patients, the two methods agreed on 19 of the samples (seven of which were not infected and nine of which were infected with E. coli), while disagreeing on eight samples, seven of which the MALDI-TOF method identified as infected while the LC-MS/MS approach identified as not infected, though these seven were identified by the MALDI-TOF at the genus, but not species level.
The authors concluded that their work demonstrates the efficiency of the method for the rapid and specific identification of the bacterial species causing UTI and could be extended in the future to other biological specimens and to bacteria having specific virulence or resistance factors. The study was published on October 4, 2019, in the journal Molecular & Cellular Proteomics.
Related Links:
Centre Hospitalier Universitaire de Québec
Latest Microbiology News
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
Troponin is a protein found in heart muscle cells that is released into the bloodstream when the heart is damaged. High-sensitivity troponin blood tests are commonly used in hospitals to diagnose heart... Read more
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more